[[ type === 'moc' ? 'MARKET ON CLOSE' : 'FREE WEBINAR' ]]
[[ timeLabel ]] WATCH LIVE:
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Join Barchart Premier to attend LIVE "Market on Close" program each Friday with John Rowland. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Bayer Ag ADR (BAYRY)

Bayer Ag ADR (BAYRY)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [OTC US]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [OTC US]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]] ([[ financialData.relativeStrengthDirection14d ]]) ([[ financialData.highPercent1y ]]) ([[ financialData.lowPercent1y ]])

Fundamentals

See More
  • Market Capitalization, $K 43,662,300
  • Shares Outstanding, K 3,930,000
  • Annual Sales, $ 51,564 M
  • Annual Income, $ -4,096 M
  • EBIT $ -1,219 M
  • EBITDA $ 1,932 M
  • 60-Month Beta 0.62
  • Price/Sales 0.85
  • Price/Cash Flow 5.12
  • Price/Book 1.49
  • Price/Earnings ttm 8.27
  • Earnings Per Share ttm 1.35
  • Most Recent Earnings $0.18 on 03/04/26
  • Next Earnings Date 05/12/26 [--]
  • Annual Dividend & Yield (Fwd) 0.02 (0.21%)
  • Most Recent Dividend 0.023 on 04/28/26
  • Sector Medical
  • INDUSTRY GROUPING Large Cap Pharma

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 13 analysts offering recommendations.
Earnings Estimates - Current Qtr 03/31/26
See More
  • Average Estimate $0.64
  • Number of Estimates 2
  • High Estimate $0.66
  • Low Estimate $0.62
  • Prior Year $0.65
  • Growth Rate Est. (year over year) -1.54%

Price Performance

See More
Period Period Low Period High Performance
1-Month
10.5300 +5.51%
on 04/29/26
12.2200 -9.08%
on 04/15/26
-0.4900 (-4.22%)
since 04/01/26
3-Month
10.2500 +8.39%
on 03/04/26
14.8500 -25.19%
on 02/17/26
-2.0400 (-15.51%)
since 01/30/26
52-Week
6.2000 +79.19%
on 05/14/25
14.8500 -25.19%
on 02/17/26
+4.6400 (+71.72%)
since 05/01/25

Most Recent Stories

More News
New Study Highlights Societal Optimism Toward Breakthrough Science, and Rising Anxiety About How Fast the World Is Changing

The Latest Breakthrough Study from Leaps by Bayer and BCG reveals why optimism varies by technology, region, and context, with varying trends in China, Germany, and the US Younger generations...

BAYRY : 11.1100 (-0.54%)
BAYZF : 44.4150 (-0.18%)
BAYN : 0.0100 (unch)
Bayer to Present 13 Abstracts From Its Stroke Franchise at ESOC 2026, Including Two Late-breaking Analyses From the Phase III OCEANIC-STROKE Trial of Asundexian

KEY FACTS Two late-breaking presentations from the landmark OCEANIC-STROKE study will provide new insights into ischemic strokes that occurred during the trial, as well...

BAYRY : 11.1100 (-0.54%)
BAYZF : 44.4150 (-0.18%)
BAYN : 0.0100 (unch)
Bayer Canada Supports New School of Medicine at Simon Fraser University (SFU) With Full Tuition Entrance Award for Inaugural Class

Bayer Canada is proud to support the Simon Fraser University (SFU) School of Medicine - the first medical school in Western Canada in nearly 60 years. The new school is dedicated to help improve primary...

BAYRY : 11.1100 (-0.54%)
BAYZF : 44.4150 (-0.18%)
BAYN : 0.0100 (unch)
Bayer Announces Leadership Change Within Pharmaceuticals’ Worldwide Markets Organization in the U.S. to Support Company’s Full Growth Potential

Nelson Ambrogio appointed to lead U.S. pharmaceuticals business, Bayer’s largest pharmaceutical growth market Appointment supports Bayer Pharmaceuticals’ strategy to renew top-line...

BAYRY : 11.1100 (-0.54%)
BAYZF : 44.4150 (-0.18%)
BAYN : 0.0100 (unch)
Bayer Crop Science Canada Redefines Canola Innovation With New "Advancing Better Canola" Initiative

Bayer challenges industry to redefine canola innovation and reframe canola's future around real, lasting systems.

BAYRY : 11.1100 (-0.54%)
BAYZF : 44.4150 (-0.18%)
BAYN : 0.0100 (unch)
Multiplatinum Rapper, Actor Ludacris Partners with One A Day® to Help People Realize that Health Does Not Need to Be Ludacris

The social-first campaign humorously tackles extreme wellness trends while showcasing how Ludacris incorporates One A Day ® multivitamins...

BAYRY : 11.1100 (-0.54%)
BAYZF : 44.4150 (-0.18%)
BAYN : 0.0100 (unch)
Bayer Crop Science Launches 2026 Opportunity Scholarship Program

Bayer Crop Science Canada is excited to support the future of Canadian agriculture with its 2026 Bayer Crop Science Opportunity Scholarship. Through the scholarship, students entering post-secondary...

BAYRY : 11.1100 (-0.54%)
BAYZF : 44.4150 (-0.18%)
BAYN : 0.0100 (unch)
KERENDIA® (finerenone) Meets Primary Endpoint in Investigational Phase III FIND-CKD Study in Patients with Non-Diabetic Chronic Kidney Disease

KERENDIA ® (finerenone) met its primary endpoint demonstrating a statistically significant improvement vs. placebo in the estimated glomerular filtration rate (eGFR) slope from baseline...

BAYRY : 11.1100 (-0.54%)
BAYZF : 44.4150 (-0.18%)
BAYN : 0.0100 (unch)
New FDA 510(k) Clearance Expands Bayer’s MEDRAD® MRXperion MR Injection System Support Across Diverse Range of MR Environments

Clearance reinforces Bayer’s continued commitment to dependable, integrated radiology solutions Expanded Tesla compatibility captures...

BAYRY : 11.1100 (-0.54%)
BAYZF : 44.4150 (-0.18%)
BAYN : 0.0100 (unch)
Bayer Reports Results for the Investigational Targeted Radionuclide Therapy 225Ac-PSMA-Trillium in Advanced Metastatic Prostate Cancer

  225 Ac-PSMA-Trillium (BAY 3563254) is an investigational targeted alpha therapy (TAT) being developed for patients with advanced metastatic castration-resistant prostate cancer (mCRPC)...

BAYRY : 11.1100 (-0.54%)
BAYZF : 44.4150 (-0.18%)
BAYN : 0.0100 (unch)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 8% Buy with a Weakest short term outlook on maintaining the current direction.

See More Share

Business Summary

Bayer AG is a life science company with core competencies in the areas of health care and agriculture. With the company's focus completely on the Life Science businesses, a new organizational structure was introduced effective Jan 1, 2016. Bayer Group now comprise exclusively of the Life Science businesses....

See More

Key Turning Points

3rd Resistance Point 11.6200
2nd Resistance Point 11.5100
1st Resistance Point 11.3100
Last Price 11.1100
1st Support Level 11.0000
2nd Support Level 10.8900
3rd Support Level 10.6900

See More

52-Week High 14.8500
Fibonacci 61.8% 11.5457
Last Price 11.1100
Fibonacci 50% 10.5250
Fibonacci 38.2% 9.5043
52-Week Low 6.2000

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.